Sign up


Match Document Document Title
8192742 Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof  
A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3B inhibitor to the subject to inhibit at least one of C3b binding to factors B and...
8192738 Targeted antibodies directed to DLL4  
The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described...
8192741 Method of treating rheumatoid arthritis with an anti-IL-6R antibody  
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6...
8192740 Pharmaceutical composition comprising anti-GRP78 antibody as active ingredient  
An object of the present invention is to provide novel pharmaceutical compositions using anti-GRP78 antibodies. More particularly, the present invention provides a novel method of cancer treatment...
8192735 Method for modulating appetite  
Method of modulating appetite and/or body weight in a subject by administering to the subject an effective amount of a MIC-1 modulating agent. The agent is selected from (i) MIC-1 inhibiting agents...
8192736 Remedy for endometriosis  
The present invention provides a therapeutic agent for endometriosis comprising an interleukin-5 antagonist as an active ingredient.
8187594 Transferrin receptor antibodies  
The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the...
8188237 Binding domain-immunoglobulin fusion proteins  
The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region...
8187604 Methods of treating with anti-factor D antibodies  
The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the...
8187595 Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I  
The present invention provides αVβ3 integrin cysteine loop domain agonists and antagonists (including peptide agonists and antagonists and analogs thereof), along with methods of using the same.
8188231 Optimized FC variants  
The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
8187596 Method of treating asthma or allergy by administering an IL-33 receptor antibody  
Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33...
8188058 Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders  
The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis...
8187598 Methods of treating cancer by administering antibodies to CD200  
Methods and compositions for regulating immunity are disclosed. For enhancing an immune response, agents that inhibit OX-2 are administered. Such methods are useful in treating cancer. For...
8187603 Antibodies to human IL-22  
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22...
8188234 1D05 PCSK9 antagonists  
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present des...
8188233 1B20 PCSK9 antagonists  
Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present des...
8187597 Combination therapy for the treatment of ocular neovascular disorders  
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The...
8187593 FcγRIIB specific antibodies and methods of use thereof  
The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind F...
8187599 Compositions and methods for suppressing fibrocytes  
The present invention relates to the ability of anti-FcγR antibodies to suppress fibrocytes. Methods and compositions for suppressing fibrocytes are provided. These methods are useful in a variety ...
8182809 Methods for treating cancer by inhibiting MIC shedding  
Described herein are compositions and methods for treating cancer, comprising administering to an individual having cancer an agent to prevent MIC shedding (initiated at the alpha-3 ectodomain of...
8182817 Antibodies to human IL-22  
The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22...
8182810 IL-B30 antibodies  
Purified genes encoding cytokine referred to as interleukin-B30 (IL-B30) from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this...
8185209 Methods to extend vision to infrared wavelengths  
In a method for visualizing an object under conditions of low ambient light, the object to be visualized is exposed to incident electromagnetic radiation having a wavelength greater than what can...
8182818 Methods of using anti-TNF antibodies for treating radiation damage to the digestive tract  
In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered...
8182811 Antibodies to CXCL13  
The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including...
8178091 Compositions and methods for the treatment of respiratory disorders  
Methods and compositions are provided for the treatment of acute lung injury and pulmonary fibrosis by administering inhibitors of IGF-1R signaling activity.
8178094 Methods for inhibiting tumor growth or reducing metastatic burden in a subject by administering FDF03 antibodies  
The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.
8178093 Method for treating infectious disease using monoclonal antibodies  
The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan ...
8178092 Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23  
The invention provides a method of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23.
8178097 Methods of treatment utilizing binding proteins of the interleukin-21 receptor  
The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods...
8173130 Antibodies against flagellin and uses thereof  
The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including,...
8173122 Methods of treatment using antibodies to neutrokine-alpha  
The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In...
8173375 Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same  
Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies...
8173424 Internalizing ErbB2 antibodies  
This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the...
8173123 Methods of treating colitis involving IL-13 and NK-T cells  
Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3)....
8173124 Method to treat using antagonistic anti-hTNFSF13b human antibodies  
Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., KD=10−8 M or less), a slow off rate for T...
8173125 Wise/Sost nucleic acid sequences and amino acid sequences  
The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The...
8168199 Dipeptidyl peptidase IV inhibitors for the treatment of schizophrenia and depression  
A method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy,...
8168181 Methods of impairing osteoclast differentiation using antibodies that bind siglec-15  
This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding...
8168182 Method for treating erectile dysfunction  
A medicament based on antibodies contains an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to endothelial nitric oxide synthase (NO synthase), the activated...
8168180 Methods and compositions for modulating angiogenesis  
Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue...
8168186 Therapeutic using a bispecific antibody  
Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of...
8168164 Targeted conjugates and radiation  
The invention relates to a method for enhancing an endogenous immune response-mediated elimination of a population of cancer cells in a host. The method comprises the steps of administering to the...
8168179 Treatment method using anti-PD-L1 antibody  
Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative...
8168178 Methods and compositions for regulating lymphocyte activity  
The present application is directed to the discovery that hedgehog gene products, and signal transduction pathways involving hedgehog, are involved in maturation of T lymphocytes. The invention...
8163281 Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis  
The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24...
8163279 IL3Rα antibody conjugates and uses thereof  
The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3Rα) chain, and compositions comprising such antibodies. The present invention provides methods for ...
8163882 Polypeptide variants with altered effector function  
The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function...
8163280 Antibodies to c-Met  
The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to c-Met, preferably human c-Met, and that function to inhibit...